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polymorphic HLA loci (Figure 1). These loci encode two
distinct classes of highly polymorphic cell surface mole-
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morphic molecule b2-microglobulin and are found onTransplantations-Immunologie
most nucleated cells. They bind and present peptidesHeidelberg D-69120
derived primarily from endogenously synthesized pro-Germany
teins (e.g., viral peptides) to CD81 T cells. The other
class I loci are significantly less polymorphic, and HLA
class I typing for clinical transplantation is generally
Introduction restricted to the HLA-A and -B loci and, in some cases,
The major histocompatibility complex (MHC) is a genetic HLA-C.
region defined initially by the rejection of skin grafts in The HLA class II molecules consist of HLA-encoded
a and b glycoprotein chains associated as heterodimersgenetically incompatible mouse strains. In humans, the
on the cell surface of antigen-presenting cells such asMHC, known as the human leukocyte antigen (HLA)
B cells, macrophages, and dendritic cells. Class II mole-region, comprises about 3 Mb located on the short arm
cules, HLA-DR, -DQ, and -DP, bind processed peptidesof chromosome 6 (6p21.3). This region contains z200
derived predominantly from membrane and extracellulargenes (Beck and Trowsdale, 1999; Shiina et al., 1999),
proteins (e.g., bacterial peptides) and present them tomany of which are involved in immune responses and
CD41 T cells. Both the HLA-DQ and -DP regions containsome of which exhibit extensive genetic polymorphism.
one functional gene for each of their a (DQA1 and DPA1)The genes encoding the HLA class I (A, B, and C) and
and b (DQB1 and DPB1) chains as well as the pseu-the class II (DR, DQ, DP) molecules are the most
dogenes DQA2, DQB2, DPA2, and DPB2. The HLA-DRpolymorphic loci in the human genome, with some loci
region, however, contains one functional gene for the a(e.g., HLA-B or DRB1) having more than 300 alleles
chain (DRA) but either one or two functional genes for(Marsh, 2000). Initially, genetic variation at these loci
the b chain, depending on the haplotype. All haplotypeswas analyzed by HLA serologic typing using reagents
encode a DRB1-encoded polymorphic polypeptide as-derived from sera of multiparous women or individuals
sociated with the monomorphic a chain. Some haplo-who had received multiple blood transfusions. In addition
types contain an additional DRB locus. The other func-to such serological typing methods, class II polymor-
tional class II DRB genes, DRB3, DRB4, and DRB5,phism was analyzed, in some cases, by cellular typing
encode a b chain that forms a second cell surface het-
methods, such as the mixed lymphocyte reaction (MLR),
erodimer with the DRA-encoded a chain on certain
in which antigenic differences were typed based on
haplotypes (see Figure 1 legend). Many other genes with
recognition by T cells rather than by the products important immune functions have also been mapped
(antibodies) of B cells. within the HLA region; however, these loci are much
The advent of recombinant DNA techniques in the less polymorphic than the HLA class I and class II loci
mid-70s allowed the molecular cloning and character- and probably play a more limited role in clinical trans-
ization of the class I and class II genes, and the introduc- plantation. HLA class II typing for bone marrow trans-
tion of polymerase chain reaction (PCR) in the mid-80s plantation is usually restricted to HLA-DR and -DQ and
made possible the analyses of the extensive allelic se- for solid organ transplantation to DR.
quence diversity at these loci. In addition, PCR, following
the determination of HLA sequence polymorphism in HLA Allelic Diversity and Population Genetics
human populations, allowed the development of a vari- As noted above, the HLA class I and class II genes are
ety of simple and rapid DNA sequence–based typing the most polymorphic coding sequences in the human
methods (Saiki et al., 1986; Erlich et al., 1991). Here, we genome. The number of alleles at these loci as well as
review the application of such methods to the clinical the number of different serological specificities (sero-
areas of solid organ transplantation and bone marrow type) are shown in Figure 1. Virtually all of this extensive
or stem cell transplantation. sequence diversity is localized, for the class II loci, to
the second exon and, for the class I loci, to the second
and third exons. The HLA class II polymorphic second
Molecular Genetics of the HLA Region exon codes for the outer domain of the a and b chains
The HLA region (6p21.3) consists of a large number that, together, form the peptide binding groove with its
characteristic b sheet floor and two a-helical walls. Theof immunologically relevant genes, including the highly
first part of the second exon encodes the b sheet floor,
and the second part encodes the a helix wall of the
groove. For the class I molecule, the peptide binding§ To whom correspondence should be addressed (e-mail: henry.
erlich@roche.com). groove is formed by a single chain; the b sheet floor
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Figure 1. Simplified Map of the HLA Region
The HLA class I and class II loci are shown in blue. HLA-DM is a nonpolymorphic class II molecule involved in the maturation of the antigen-
presenting class II molecules DR, DQ, and DP. The number of alleles (as of 2000) is shown below each locus as is the number of serological
specificities (serotypes). Kilobase distances between loci are shown above the colored boxes. For class II MHC loci, a (A) and b (B) chain
descriptors are shown below the colored boxes. The number of alleles at each MHC locus is shown in bold below the a and b chain descriptors,
and the number of serotypes at each locus is shown in italics. In general, the DRB3 locus is found on haplotypes where DRB1 is *03, *11,
*12, *13, or *14; the DRB4 locus is found on haplotypes where DRB1 is *04, *07, and *09; and the DRB5 locus is found on haplotypes where
DRB1 is 15 or 16 (*15 and *16 are subtypes of the serological type DR2). DRB1*01, *08, and *10 haplotypes typically have only the DRB1 locus.
and two a-helical walls are encoded by the second and diversity. Different populations tend to have different
frequency distributions of alleles and exhibit differentthird exons.
The patterns of allelic sequence diversity for both the patterns of linkage disequilibrium. In general, the HLA
region is characterized by very strong linkage disequilib-class I and class II loci are highly unusual; some alleles
differ in the second and third exons by as much as 15%, rium that may be attributed, among other factors, to
selection for particular combinations of alleles. In someand the sequence variation is distributed as a patchwork
of localized polymorphic sequence motifs. The exten- so-called “extended haplotypes,” significant linkage
disequilibrium extends over 3 Mb from HLA-A, at thesive allelic diversity at these loci is thought to have been
generated by recombinational mechanisms like gene telomeric end of the HLA region, to HLA-DP, at the
centromeric end (i.e., the HLA-A*0101-B*0801-C*0701-conversion–like events or, to a lesser extent, by recipro-
cal recombination, which have shuffled these polymor- DRB1*0301-DQA1*0501-DQB1*0201-DPA1*0201-DPB1*
0101 haplotype among Caucasians). In fact, given thephic sequence motifs (Erlich and Gyllensten, 1991). Of
course, point mutation has also contributed to the allelic large number of alleles at the different HLA loci, it is, in
part, this strong linkage disequilibrium that allows thesequence diversity at the HLA loci. One consequence
of this pattern of patchwork polymorphism is that, in identification of bone marrow or stem cell donors in
population registries who are matched at multiple lociPCR-based HLA typing, a large number of different al-
leles can be distinguished by using a relatively modest with a given patient/recipient (see below).
number of oligonucleotide primers or probes (see below)
that recognize these discrete sequence motifs. Another HLA DNA Typing Methods
The analysis of HLA polymorphism based on DNA se-more problematic consequence is that a given pattern
of sequence motifs, detected either with probes or prim- quence variation offers a number of advantages over
the serological or cellular typing methods. DNA methodsers or by sequencing, may be consistent with more than
a single genotype because the observed sequence mo- permit the typing of a much wider variety of samples
because the viability of the cells or the expression oftifs can be combined into more than a unique pair of
alleles. This problem of “ambiguity” in DNA-based typ- the relevant HLA antigen on the cell surface is not re-
quired as it is in serological typing. The initial approaching is discussed below.
Although a very large number of alleles (e.g., .300 to HLA DNA typing involved the use of labeled cDNA
clones or genomic fragments as hybridization probesfor HLA-DRB1) can be found in the global human popula-
tion, a much smaller number (e.g., 30–50 for HLA-DRB1) in Southern blots and the correlation of restriction frag-
ment length polymorphism (RFLP) patterns with HLAis present in most individual populations, and many pop-
ulations that have gone through bottlenecks or founding serotypes. Although an informative method, RFLP typ-
ing required a large amount of high molecular weightevents (e.g., Native Americans) show more limited allelic
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genomic DNA, and the relatively cumbersome proce- a panel of probes specific for informative sequence mo-
tifs, the HLA alleles in the sample could be inferred fromdure was not well suited to routine clinical typing. The
most important limitation, however, was that most of the pattern of probe reactivity (Erlich et al., 1991). The
probes, labeled initially with P32, are now typically la-the polymorphic restriction sites used for typing were
not in exon 2 or exon 3, and, consequently, this method beled either directly with an enzyme (e.g., HRP) or with
biotin. The biotin-labeled probes can be detected withrelied on linkage disequilibrium between these flanking
sites and the sequence polymorphism in these exons. streptavidin conjugated to HRP (or AP) and can be used
with chromogenic or chemoluminescent subtrates forThus, although RFLP analysis permitted typing at the
broad serotype level and, in some cases, could subdi- sensitive, simple, and robust detection. More recently,
digoxigenin-labeled probes and antibody to digoxigeninvide these types, it failed to distinguish much of the HLA
class I and class II sequence diversity. detection methods have been introduced.
Currently, computer programs are routinely used toThe study of the allelic diversity at the HLA loci as
well as the development of simple and rapid DNA-based infer the genotype from the probe reactivity pattern. The
genotype interpretation programs have to be updatedtyping methods was dramatically facilitated by the de-
velopment of PCR amplification. In general, sequence- periodically to incorporate newly identified alleles. In
some cases, the identification of new alleles and theirbased typing methods allow a more accurate (fewer
errors) and much more precise (more discriminating) introduction into the genotyping software may require
the addition of probes to the typing system. In mostmethod of typing than serological or cellular methods.
For example, there are .300 alleles at the DRB1 locus cases, however, the new allele represents a new combi-
nation of known polymorphic sequence motifs recog-but only 17 distinct serological specificities or serotypes
(see Figure 1). In addition, unlike serological typing re- nized by existing probes and, thus, does not create the
need for additional probes. In this case, however, theagents, the primers, probes, and thermostable DNA
polymerases used in PCR-based HLA typing can be incorporation of the new allele into the typing system
and software may create additional ambiguities, arisingproduced as standardized reagents. PCR amplification
also makes possible the HLA typing of minute samples when a given probe reactivity pattern is consistent with
more than one genotype. Given enough primers andsuch hair, buccal swabs, dried blood spots, or even
individual cells. Finally, PCR-based typing data from probes, the PCR/SSO method is, in principle, capable
of distinguishing all of the alleles at a given HLA locus.which the nucleotide sequence of the amplified locus
can be inferred can reveal where and how alleles differ, To achieve allele-level typing, however, it is usually nec-
essary to amplify separately the alleles of a heterozygoteallowing the analysis of the role of specific polymorphic
amino acid residues in peptide binding and presentation (see below) and analyze the probe reactivity pattern for
each individual allele.as well as in disease association and clinical trans-
plantation outcomes (see below). In the SSO probe typing approach, the sequence of
the primers and the amplification reaction conditionsBased on the available database of class I and class II
allelic sequence diversity, a variety of PCR-based typing (thermal profile, Mg21 concentration, primer concentra-
tions, etc.) are designed so that all alleles at the targetmethods have been developed and applied to clinical
HLA typing. locus are amplified in a single PCR, and, whenever pos-
sible, the amplification is locus specific. In some cases,Most typing methods involve the design of primer
pairs that are capable of amplifying all alleles at the such as generic DRB typing, the same primer pairs am-
plify the DRB1, DRB3, DRB4, and DRB5 second exons.target locus with the polymorphic sequence motifs lo-
calized between the primer sites. The sequences be- This approach allows the typing of all these loci from a
single PCR. On the other hand, amplification of moretween the primers are subsequently characterized by a
variety of analytic approaches, including hybridization than one locus can complicate the interpretation of
probe reactivity if the complementary sequence motifwith oligonucleotide probes, digestion with restriction
enzymes, and chain termination sequencing reactions, is found in more than one locus. In the case of DRB1,
it is difficult to find a single primer pair that is locusor are inferred from the conformation-based mobility of
the PCR products using gel electrophoresis. The other specific and that also amplifies all alleles of DRB1.
Following the initial SSO probe typing system formain approach to HLA typing uses the PCR itself as a
method of distinguishing polymorphisms by exploiting DQA1, PCR/SSO dot blot typing systems for DRB1,
DQB1, DPB1, and DPA1 have been developed as wellthe specificity of oligonucleotide primer extension and
places the 39 end of the primer at the polymorphic site. as, more recently, for the HLA-A, B and C loci. In dot
blot typing, as the number of probes in the typing system
and, hence, the number of separate hybridizations in-Typing by Hybridization to Sequence-Specific
creases, the procedure can be somewhat cumbersome,Oligonucleotide Probes
particularly for the typing of small numbers of samples.The first PCR-based approaches to HLA typing utilized
Reverse hybridization approaches using immobilizedlabeled sequence-specific oligonucleotide (SSO) probes
SSO probe arrays and labeled PCR products, developedto hybridize to PCR products amplified from the sample
to simplify SSO typing, are described below.and immobilized on a nylon or nitrocellulose filter—the
“dot blot” method (Saiki et al., 1986). Under appropriate
hybridization and wash conditions, the labeled SSO Typing Based on Differential Primer Extension
and Sequence-Specific Amplificationprobes would bind only to the complementary sequence
in the amplified DNA immobilized on the filter and were Another PCR-based approach, based on the specificity
of primer extension rather than that of probe hybridiza-able to distinguish single nucleotide differences. Using
Immunity
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tion, has also been applied to HLA typing. This method and Erlich, 1995) of HLA polymorphism have greatly
is known variously as allele-specific amplification (ASA) facilitated PCR-based typing with multiple probes. The
(Wu et al., 1989), sequence-specific priming (SSP) (New- conventional dot blot involved an immobilized PCR
ton et al., 1989), and the amplification refractory muta- product that is hybridized to each of many labeled SSO
tion system (ARMS) (Olerup and Zetterquist, 1992). Here, probes. The “reverse blot” (or immobilized probe)
a specific primer pair is designed for each polymorphic method is based on the hybridization of PCR product,
sequence motif or pair of motifs and is based on the labeled with biotinylated primers during the amplifica-
differential ability to extend a primer that is matched or tion, to an array of immobilized probes on a membrane.
mismatched with the template at the 39 end. The pres- A variety of immobilization methods can now be used.
ence of the two targeted polymorphic sequences in a The presence of the PCR product bound to a specific
sample is detected as a positive PCR product, typically probe at a specific location is detected using streptavi-
identified as a band on a gel. In SSP/ARMS typing, if din-HRP and a chromogenic substrate. This procedure
the PCR is negative and no product is detected, the requires only a single PCR and a single hybridization
sample is assumed to lack one or both of the specific reaction to obtain information from the entire SSO probe
motifs. Since inhibition of the PCR or absence of tem- panel; all of the probe reactivity information is contained
plate also yields a negative result, each reaction should on a single membrane, making it amenable to automat-
include a positive control, that is, PCR primers for an ing the hybridization, wash, and color development as
unrelated monomorphic target sequence that produces well as the data capture and interpretation. The critical
a fragment that can be distinguished (e.g., resolved by challenge in this approach is to design a large number
differential gel mobility) from the HLA PCR product. One of SSO probes that will hybridize specifically under a
virtue of SSP/ARMS typing is that it can “set phase,” in single set of conditions. In addition, because the PCR
that the two polymorphic sequence motifs detected by product is denatured and hybridized in solution to the
the primers must be linked on the same allele. SSP/ immobilized complementary probe, secondary structure
ARMS typing methods have been developed for both in the labeled target single strand that would prevent
the class I and class II loci, and the introduction of binding to the probe must be minimized.
robotics has, in some cases, simplified this procedure. This approach has been applied to a variety of genetic
Detection methods that are not based on visualizing a typing systems and was the basis for the first commer-
band in a gel and can therefore eliminate the gel electro- cial PCR test, the AmpliType HLA-DQ-a Forensic test.
phoresis step have been developed recently. Although In order to accommodate more probes on the mem-
informative and relatively fast for small numbers of sam- brane, the probes are now immobilized as lines rather
ples, the SSP approach requires many separate PCR’s than as dots (Figure 2). A commercially available HLA-
to achieve intermediate or high level typing and, in its DRB test, the DYNAL/Reli HLA-DRB test, uses 36 probes
current format, is not well suited to rapid throughput and provides intermediate-level typing for alleles at the
of a large sample of numbers. As noted above, allele- DRB1, DRB3, DRB4, and DRB5 loci. Immobilized probe
specific amplification can be used in conjunction with tests using the same PCR thermal profile and hybridiza-
SSO probe typing for high-resolution typing by allowing tion conditions have been developed for DQB1 and the
the separate amplification of the two alleles in a hetero- HLA class I loci, A, B, and C and are also commercially
zygote. available. Our current higher resolution research B locus
typing system uses 83 probes for exons 2 and 3, which
Typing Based on the Gel Mobility are coamplified with two primer pairs, and our research
of the PCR Products HLA-A typing system uses 57 immobilized probes. Two
Other PCR-based methods involve the use of multiple instruments to automate the hybridization, wash, and
restriction endonucleases and gel electrophoresis color development of these immobilized probe strips are
(PCR-RFLP) to characterize the polymorphisms in the
commercially available (SLT Profiblot and the DYNAL
PCR product; these approaches have been developed
Autoreli48) as is software to read and interpret the probe
for class I and class II typing. Conformation-based gel
reactivity patterns. The immobilized probe approach ismobility analyses, such as PCR-SSCP (single strand
well suited to the rapid typing of a few samples as wellconformation polymorphism) and PCR-DHA (directed
as to high-throughput typing of large sample numbers.heteroduplex analysis), have also been developed for
As noted above, high-resolution typing often requiresclass II typing, but these approaches, unlike SSO or
the separate amplification of the two alleles in a hetero-SSP methods, are not widely used in clinical settings.
zygote. For this purpose, primers designed to polymor-A recent modification of the directed heteroduplex ap-
phic regions with many sequence variants (i.e., codonsproach, termed double-stranded conformation analysis
9–12 of DRB1, a region with eight different sequence(DSCA), utilizes a fluorescent single-stranded probe
motifs) are valuable to carry out allele-specific amplifica-specific for a particular HLA allele (i.e., HLA-A*0101) to
tion. Figure 2 shows the probe reactivity pattern, definedhybridize to the PCR products (e.g., the two HLA-A al-
by the blue lines on the nylon strip, for the HLA-A locusleles) amplified from the sample, thereby generating la-
for a panel of homozygous and heterozygous cells.beled heteroduplex molecules. The mobility of these
labeled molecules can be systematically compared to
Sequence-Based Typinga standard set of markers for each allele (Arguello, 1998).
The application of semiautomated chain termination se-
quencing using either fluorescent primers or fluorescentReverse Hybridization with Immobilized
dideoxy terminators, with the development of appro-SSO Probe Arrays
priate sequence analysis software, has become a pow-Reverse hybridization approaches to SSO probe analy-
sis (Saiki et al., 1989; Bugawan et al., 1994; Begovich erful approach to allele-level HLA typing. Several com-
Review
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Figure 2. HLA-A-Immobilized SSO Probe Line Array Strips
Seven HLA-A line array strips (labeled 1–7) are shown with the probe reactivity patterns detected using Streptavidin-HRP and TMB, a
chromogenic substrate. The inferred heterozygous and homozygous HLA-A genotypes are shown on the right. The black reference line and
control probe lines for HLA-A exon 2 and exon 3 are indicated along the bottom of the figure. Positively reacting probes appear as blue lines.
Control probes (that hybridize to all alleles) are titered to be lower in signal intensity than all other positive probes, permitting quantitative
discrimination between truly positive probes and any cross-hybridizing probe.
mercial approaches to automating the gel electrophore- Mechanisms of Alloreactivity
sis step are now available, and, recently, the introduction Graft rejection by the host as well as graft versus host
of modified thermostable DNA polymerases capable of disease, the attack of recipient tissue by the bone mar-
efficiently incorporating fluorescent dideoxy nucleo- row stem cell graft, is mediated by alloreactive T cells
tides has made sequencing a more robust typing (Dennert et al., 1985; Hansen et al., 1997). HLA molecules
method. The recent introduction of capillary-based sys- have a major effect in transplantation, due to the funda-
tems has increased the throughput and decreased the mental role they play in T cell activation and the allo-
cost of HLA sequence-based typing. High-resolution response. A significant proportion of circulating T cells
typing by sequencing, which requires the separate am- are alloreactive, that is, they recognize “foreign” or “non-
plification and analysis of the two alleles, is sometimes self” HLA. The structural differences encoded by se-
carried out for the final matching of bone marrow donor quence polymorphisms in the class I and class II HLA
and recipient. However, in its current format, SBT is still genes and the minor histocompatibility antigens (mHA)
a somewhat expensive procedure and not ideally suited presented by class I and class II molecules induce T
to large-scale typing or routine clinical typing. cell activation and immune reactions mediated by allore-
active T cells and B cells producing anti-HLA antibodies.
The polymorphic residues that define each unique HLAHLA Typing Requirements
molecule are located within or very near the peptideIn general, the desired resolution and properties of a
binding groove (Parham, 1992). These differences mayPCR-based HLA typing method will depend on the ap-
alter the size, shape, and charge of the contact sitesplication. Bone marrow donor registry screening and
for peptide binding and thereby profoundly change therecruitment requires a method that provides intermedi-
repertoire of peptides that are bound (Rammensee,ate-level resolution typing and is low cost and high
1995). The genetic differences recognized by alloreac-throughput. The typing data should facilitate the cost-
tive T cells reflect the sequence polymorphisms in HLAeffective storage and search of the donor typings for A,
molecules and the mHA HLA-bound peptides encodedB, and DRB1 in the donor registry for possible matches
by biallelic genes that distinguish donor and recipient.with the patient/recipient. The final HLA typing for
Allorecognition can be classified as the “direct” or thematching potential bone marrow donors and recipients
“indirect” pathway. Direct alloreactivity refers to the di-should be done with a method that allows high-resolu-
rect recognition of foreign HLA-peptide complexes,tion typing and should include the DRB1, DQB1, and
whereas indirect recognition refers to foreign HLA mole-the A, B, and C loci. For solid organ transplantation, the
cules and mHA that are processed by host APC andtyping methods should be relatively fast and provide
presented by host HLA. If we consider the clinicallyan intermediate level of resolution for the A, B, and
DRB1 loci. critical graft versus host disease in a bone marrow trans-
Immunity
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Figure 3. Kidney Graft Survival and HLA Matching
P values for correlations of HLA matches with graft survival were based on a “weighted regression analysis.” It considers the number of
patients studied in each group and “expects” a stepwise decline in success from zero to six mismatches (Dunn and Clark, 1974). With the
large patient numbers analyzed, p values were usually less than 0.0001 (Collaborative Transplant Study, University of Heidelberg, Germany).
The international reference source for organ transplant survival data is http://www.ctstransplant.org. (A) Comparison of kidney graft survival
with related and cadaveric donors. (B) Survival of cadaveric kidney transplants and HLA-A, -B, and -DR matching. (C) Survival of cadaveric
kidney transplants with limited cold ischemia. (D) Survival of cadaveric kidney transplants with most recent immune suppression protocols.
All patients who received any of the three drugs Neoral, FK506, and/or MMF (in any combination) were included. (E) Cadaveric kidney transplant
survival and DNA matching at HLA-DRB among serogically matched donors. The two curves were compared using the log rank test (p ,
0.0001).
plant, in the direct pathway, alloreactive donor T cells (foreign) peptide. Direct alloreactivity is thought to con-
tribute primarily to acute rejection, whereas indirect allo-specific for the recipient HLA molecule can recognize
and attack recipient cells that bear this foreign molecule. recognition may be responsible for sustaining chronic
rejection.In the indirect pathway, donor T cells can also recognize
donor cells with self HLA that have bound a recipient T cells and B cells may not be the only mediators of
Review
353
matched sibling. Registries of HLA-typed unrelated
bone marrow donors have been developed and can be
searched to find phenotypically matched potential do-
nors. Given the extensive polymorphism at the HLA loci,
the probability of finding a serologically matched donor
at three loci (i.e., A, B, and DRB1) is very low, requiring
registries consisting of millions of potential bone marrow
donors to provide a matched donor for most patients
(www.bmdw.org). Given the allelic sequence diversity
within a serotype, the probability of finding a DNA-
matched donor is even lower, making the concept of
“permissible” mismatches (see below) a clinically rele-
vant issue. The bone marrow transplant HLA data dis-
cussed here are based on typing at high (allele level)
resolution. The large data set for solid organ transplanta-
tion discussed here relies primarily on serologic typing.
Thus, the power of DNA typing to distinguish allelic
variants within a serological group (i.e., any of the .30
DRB1*04 alleles within the DR4 serotype) and the effect
on graft survival and acute graft versus host disease isFigure 4. Heart Transplant Survival and HLA-A, -B, and -DR
restricted to the studies of bone marrow transplantationMatching
(see below). As a result of the different levels of HLA
typing, the meaning of a “mismatch” differs in these two
studies; in the solid organ transplant, mismatch meansalloimmunity, especially in marrow transplantation. The
a serotype difference (e.g., DR4 versus DR3), while, inrecent discovery of a family of genes encoding natural
the bone marrow studies of chronic myeloid leukemiakiller cell (NK-KIR) receptors, known to interact with
(CML) recipients, mismatch refers to an allele differencespecific polymorphic epitopes on HLA class I molecules,
(i.e., DRB1*0401 versus DRB1*0404) between individu-has suggested the participation of NK cells in graft rejec-
als with the same serotype (DR4). As a consequence oftion and possibly GVHD (Colonna et al., 1992; Litwin et
the different ways that donors are identified or recruitedal., 1994; Valiante and Parham, 1997; Winter et al., 1998).
for bone marrow and solid organ transplants, bone mar-The consequences of mismatching at different HLA
row donors are more likely to be serologically matchedloci may be different for these different pathways. In
with the recipient than are solid organ donors. Althoughgeneral, precise HLA class I and class II matching ap-
these solid organ transplants involve typing only at thepears to be more critical for bone marrow or stem cell
serologic level of resolution, these studies have muchtransplantation than for solid organ transplantation be-
larger numbers and, hence, greater statistical powercause, among other factors, the graft is immunologically
than do the bone marrow transplant studies.competent and, thus, the immune recognition is bidirec-
tional, involving the response of the graft to the host as
Solid Organ Transplantationwell as that of the host to the graft (Hansen et al., 1997).
The analysis of the role of HLA matching for kidney graft
survival over the period 1985–1999 is, as noted above,HLA and Transplantation
primarily based on serologic typing data. The compari-HLA-matched sibling bone marrow or stem cell donors
son of DNA typing and serology that indicates that DNA-are, with the exception of very rare recombination
matched grafts survive better than do serologicallyevents, genotypically identical at all HLA loci with the
matched grafts (see below) probably reflects differencespatient. Most patients, however, do not have an HLA-
in accuracy (fewer errors for DNA typing) rather than
greater discrimination, because, in these comparisons,
the DNA typing was carried out at a low to intermediateTable 1. Bone Marrow Graft Failure According to Donor HLA Dis-
level of resolution (does not distinguish all alleles).parity
For kidney transplants, the significance of HLA match-
Donor Disparity Graft Failures (%) ing for graft survival is illustrated in Figure 3A by compar-
Allele-matched for HLA-A, -B, 3 (2%) ing related and cadaveric donors. The half-life survival
and -C for a graft from an HLA-identical sibling is 23.4 years
Single allele mismatch for 1 (2%) compared to a one haplotype–related donor with a half-
HLA-A, -B, or -C
life of 12.8 years and to a cadaveric donor with a half-Multiple alleles mismatch 9 (29%)
life of 11.1 years. The effect of serologic mismatchesfor HLA-A, -B, and/or -C
at either the HLA-A, -B, or -DR loci for the survival ofSingle allele mismatch for 0
HLA-DR or -DQ cadaveric kidney transplants is shown in Figure 3B. Con-
Multiple allele mismatches for 0 trary to some claims, HLA matching has a statistically
HLA-DR and/or -DQ significant effect on kidney graft survival even under
Class I and class II mismatches 4 (12%)
conditions of very short ischemia (0–6 hr under optimal
Graft failure among 300 patients with chronic myeloid leukemia that local transport conditions) (Figure 3C). The effect of HLA
were transplanted with marrow from an unrelated donor (Petersdorf matching is, as expected, enhanced with presensitized
et al., 1998).
recipients (panel reactive antibody [PRA] .50%; data
Immunity
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Figure 5. Probability of Grades III–IV Acute
GVHD in Patients with Chronic Myeloid Leu-
kemia Transplanted with Marrow Cells from
an Unrelated Donor According to HLA Allele
Match
All recipients were treated with methotrexate
and cyclosporin A (Csp).
not shown) and is also statistically significant among DP) (Mytilineos et al., 1997) as well as DNA typing that
distinguishes alleles within a serotype can have clinicalkidney grafts from unrelated living donors (data not
shown). HLA-A, -B, and -DR matching remains signfi- relevance in cadaveric kidney transplants. In both of
these studies, the enhanced graft survival was observedcant for cadaveric kidney tranplants, even with the most
recent forms of immunosuppression (Figure 3D). The only in presensitized (retransplant) recipients. The effect
of HLA-A, -B, and -DR matching on the survival of hearteffect of HLA matching is relatively weak over the first
2 years and emerges over time, suggesting that the new transplants is also statistically significant (Figure 4) but
not for liver transplants (data not shown).drugs are more potent in avoiding early acute rejections.
However, as the drug dosages are tapered over time,
the HLA-matching effect becomes significant. DNA typ- HLA Matching and Marrow or Hematopoietic
Stem Cell Transplantationing for HLA-DRB1, albeit at an intermediate level of reso-
lution, provides better cadaveric kidney graft survival The analysis of the role of HLA matching for HSC trans-
plantation has largely depended on the development ofthan does serological typing (Figure 3E). This effect is
probably due, given the serological level of the DNA- high-resolution typing for completely defining the poly-
morphism of HLA-A, -B, -C, DRB1, and DQB1 alleles inbased HLA typing, to enhanced accuracy rather than to
increased discrimination (better allelic definition). Re- patients and donors. HLA compatibility affects not only
the ability to achieve sustained engraftment of donorcent studies, however, have indicated that the DNA typ-
ing of loci that cannot be typed serologically (i.e., HLA- HSC but also the risk of developing acute and chronic
Figure 6. Probability of Survival in Patients
with Chronic Myeloid Leukemia Transplanted
with Marrow Cells from an Unrelated Donor
According to HLA Allele Match
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